and/or

48 Trending Topics found

Major Developments in Hematology-Oncology to Be Reported at ASH Annual Meeting

The largest hematology-oncology meeting in the world will take place in Orlando, Florida from December 5 through 8. Memorial Sloan Kettering experts are available to comment on breaking news out of the meeting. For more information and to set up interviews or access photos and video, email Rebecca Williams, williamr@mskcc.org.

  • Thursday, December 3, 2015

A Better Way to Measure Cancer Survival Outcomes Among US Hospitals?

Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. Now, a new MSK study in JAMA Oncology explores a potential way to profile US hospitals by performance so, eventually, patients can make more informed decisions about their care. For more information and to set up interviews, email Jeanne D’Agostino at DAgostiJ@mskcc.org.

  • Thursday, October 8, 2015

First-Ever Combination Immunotherapy Receives Approval by the FDA

The US Food and Drug Administration approved the immunotherapy combination nivolumab (Opdivo®) plus ipilimumab (Yervoy®) for use in patients with metastatic melanoma. Memorial Sloan Kettering’s medical oncologist and cancer immunologist Jedd Wolchok, created and tested the combination and led the clinical trials that resulted in FDA approval. Patients who have received this new drug combination are also available for interview. For more information and to set up interviews, email Nicole McNamara at mcnamarn@mskcc.org.

  • Thursday, October 1, 2015

New Research Presented at 2015 European Cancer Congress Meeting

Memorial Sloan Kettering experts are available to comment on research presented at the 2015 European Cancer Congress, including research in immunotherapy, breast, lung, bladder, prostate, and kidney cancers, among others. For more information and to set up interviews or access photos and video, email Rebecca Williams, williamr@mskcc.org.

  • Thursday, September 24, 2015

Exciting New Research at the 2015 ASCO meeting

MSK experts are available to comment on research presented at the 2015 annual meeting of the American Society of Clinical Oncology, including exciting new findings on how immunotherapy is helping patients with many cancers. For more information on MSK's research at the meeting and to set up interviews or access photos and video, email Caitlin Hool at hoolc@mskcc.org.

  • Thursday, May 28, 2015

Promising New Research at the 2015 AACR Annual Meeting

Memorial Sloan Kettering experts are available to comment on the exciting new research presented at the 2015 American Association of Cancer Research annual meeting, including research in immunotherapy in pediatric cancers and melanoma, breast cancer, and many others. For more information and to set up interviews or access photos and video, email Rebecca Williams at williamr@mskcc.org.

  • Saturday, April 18, 2015

Exciting Developments, New Research in Breast Cancer: San Antonio Breast Cancer Symposium

Memorial Sloan Kettering breast cancer experts are available to comment on breaking news out of this year’s annual meeting set to take place December 9 through 13.

  • Monday, December 8, 2014

Major Developments in Hematology-Oncology to Be Reported at ASH Annual Meeting

The largest hematology-oncology meeting in the world will take place in San Francisco from December 6 through 9. Memorial Sloan Kettering experts are available to comment on breaking news out of the meeting.

  • Tuesday, December 2, 2014

Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures

A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.

  • Wednesday, November 19, 2014

Medicare Says It Will Cover Lung Cancer Scans for Long-Time Smokers

The Centers for Medicare and Medicaid Services made a formal proposal to start covering low-dose CT scans for people who fall into a high-risk category for lung cancer. Epidemiologist Peter B. Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes and a thought leader on this topic, is available to discuss the importance of the proposal. For more information and to set up an interview, email our media staff at mediastaff@mskcc.org.

  • Tuesday, November 11, 2014